Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Uwe Christians to Sirolimus

This is a "connection" page, showing publications Uwe Christians has written about Sirolimus.

 
Connection Strength
  
 
 
6.801
  
  1. Shokati T, Hartmann M, Davari B, Klawitter J, Klawitter J, Christians U. Temsirolimus metabolic pathways revisited. Xenobiotica. 2020 Jun; 50(6):640-653.
    View in: PubMed
    Score: 0.567
  2. Klawitter J, Nashan B, Christians U. Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf. 2015 Jul; 14(7):1055-70.
    View in: PubMed
    Score: 0.415
  3. Klawitter J, Klawitter J, Schmitz V, Shokati T, Epshtein E, Thurman JM, Christians U. Mycophenolate mofetil enhances the negative effects of sirolimus and tacrolimus on rat kidney cell metabolism. PLoS One. 2014; 9(1):e86202.
    View in: PubMed
    Score: 0.381
  4. Strom T, Shokati T, Klawitter J, Klawitter J, Hoffman K, Schiebel HM, Christians U. Structural identification of SAR-943 metabolites generated by human liver microsomes in vitro using mass spectrometry in combination with analysis of fragmentation patterns. J Mass Spectrom. 2011 Jul; 46(7):615-24.
    View in: PubMed
    Score: 0.318
  5. Steudel W, Dingmann C, Zhang YL, Bendrick-Peart J, Clavijo C, Shulze J, Betts R, Christians U. Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals. J Clin Pharmacol. 2011 Jan; 51(1):29-39.
    View in: PubMed
    Score: 0.291
  6. Schmitz V, Klawitter J, Bendrick-Peart J, Schoening W, Puhl G, Haschke M, Klawitter J, Consoer J, Rivard CJ, Chan L, Tran ZV, Leibfritz D, Christians U. Metabolic profiles in urine reflect nephrotoxicity of sirolimus and cyclosporine following rat kidney transplantation. Nephron Exp Nephrol. 2009; 111(4):e80-91.
    View in: PubMed
    Score: 0.272
  7. Filler G, Bendrick-Peart J, Strom T, Zhang YL, Johnson G, Christians U. Characterization of sirolimus metabolites in pediatric solid organ transplant recipients. Pediatr Transplant. 2009 Feb; 13(1):44-53.
    View in: PubMed
    Score: 0.256
  8. Filler G, Bendrick-Peart J, Christians U. Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther Drug Monit. 2008 Apr; 30(2):138-42.
    View in: PubMed
    Score: 0.254
  9. Strom T, Haschke M, Boyd J, Roberts M, Arabshahi L, Marbach P, Christians U. Crossreactivity of isolated everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus. Ther Drug Monit. 2007 Dec; 29(6):743-9.
    View in: PubMed
    Score: 0.248
  10. Strom T, Haschke M, Zhang YL, Bendrick-Peart J, Boyd J, Roberts M, Arabshahi L, Marbach P, Christians U. Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients. Ther Drug Monit. 2007 Oct; 29(5):592-9.
    View in: PubMed
    Score: 0.246
  11. Boernsen KO, Egge-Jacobsen W, Inverardi B, Strom T, Streit F, Schiebel HM, Benet LZ, Christians U. Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus. J Mass Spectrom. 2007 Jun; 42(6):793-802.
    View in: PubMed
    Score: 0.240
  12. Zhang YL, Bendrick-Peart J, Strom T, Haschke M, Christians U. Development and validation of a high-throughput assay for quantification of the proliferation inhibitor ABT-578 using LC/LC-MS/MS in blood and tissue samples. Ther Drug Monit. 2005 Dec; 27(6):770-8.
    View in: PubMed
    Score: 0.216
  13. Filler G, Womiloju T, Feber J, Lepage N, Christians U. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. Am J Transplant. 2005 Aug; 5(8):2005-10.
    View in: PubMed
    Score: 0.211
  14. Christians U, Gottschalk S, Miljus J, Hainz C, Benet LZ, Leibfritz D, Serkova N. Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors. Br J Pharmacol. 2004 Oct; 143(3):388-96.
    View in: PubMed
    Score: 0.198
  15. Jacobsen W, Serkova N, Hausen B, Morris RE, Benet LZ, Christians U. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc. 2001 Feb-Mar; 33(1-2):514-5.
    View in: PubMed
    Score: 0.155
  16. Serkova N, Hausen B, Berry GJ, Jacobsen W, Benet LZ, Morris RE, Christians U. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. J Pharmacol Exp Ther. 2000 Jul; 294(1):323-32.
    View in: PubMed
    Score: 0.149
  17. Serkova N, Litt L, Leibfritz D, Hausen B, Morris RE, James TL, Benet LZ, Christians U. The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates. Br J Pharmacol. 2000 Feb; 129(3):485-92.
    View in: PubMed
    Score: 0.144
  18. Serkova N, Litt L, James TL, Sad?e W, Leibfritz D, Benet LZ, Christians U. Evaluation of individual and combined neurotoxicity of the immunosuppressants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy. J Pharmacol Exp Ther. 1999 May; 289(2):800-6.
    View in: PubMed
    Score: 0.137
  19. Segarra I, Brazelton TR, Guterman N, Hausen B, Jacobsen W, Morris RE, Benet LZ, Christians U. Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin. J Chromatogr B Biomed Sci Appl. 1998 Dec 11; 720(1-2):179-87.
    View in: PubMed
    Score: 0.133
  20. Mizuno T, Fukuda T, Christians U, Perentesis JP, Fouladi M, Vinks AA. Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group. Br J Clin Pharmacol. 2017 05; 83(5):1097-1107.
    View in: PubMed
    Score: 0.116
  21. Emoto C, Fukuda T, Mizuno T, Schniedewind B, Christians U, Adams DM, Vinks AA. Characterizing the Developmental Trajectory of Sirolimus Clearance in Neonates and Infants. CPT Pharmacometrics Syst Pharmacol. 2016 08; 5(8):411-7.
    View in: PubMed
    Score: 0.113
  22. Emoto C, Fukuda T, Mizuno T, Cox S, Schniedewind B, Christians U, Widemann BC, Fisher MJ, Weiss B, Perentesis J, Vinks AA. Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1. Ther Drug Monit. 2015 Jun; 37(3):395-9.
    View in: PubMed
    Score: 0.104
  23. Shihab F, Christians U, Smith L, Wellen JR, Kaplan B. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Transpl Immunol. 2014 Jun; 31(1):22-32.
    View in: PubMed
    Score: 0.097
  24. Lemos PA, Farooq V, Takimura CK, Gutierrez PS, Virmani R, Kolodgie F, Christians U, Kharlamov A, Doshi M, Sojitra P, van Beusekom HM, Serruys PW. Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention. 2013 May 20; 9(1):148-56.
    View in: PubMed
    Score: 0.091
  25. Bohra R, Sch?ning W, Klawitter J, Brunner N, Schmitz V, Shokati T, Lawrence R, Arbelaez MF, Schniedewind B, Christians U, Klawitter J. Everolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the rat. PLoS One. 2012; 7(10):e48063.
    View in: PubMed
    Score: 0.087
  26. Gottschalk S, Cummins CL, Leibfritz D, Christians U, Benet LZ, Serkova NJ. Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism. Neurotoxicology. 2011 Jan; 32(1):50-7.
    View in: PubMed
    Score: 0.076
  27. Ostojic MC, Perisic Z, Sagic D, Jung R, Zhang YL, Bendrick-Peart J, Betts R, Christians U. The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: the Stealth PK Study. Eur J Clin Pharmacol. 2011 Apr; 67(4):389-398.
    View in: PubMed
    Score: 0.076
  28. Tada N, Virmani R, Grant G, Bartlett L, Black A, Clavijo C, Christians U, Betts R, Savage D, Su SH, Shulze J, Kar S. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv. 2010 Apr; 3(2):174-83.
    View in: PubMed
    Score: 0.073
  29. Klawitter J, Gottschalk S, Hainz C, Leibfritz D, Christians U, Serkova NJ. Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. Chem Res Toxicol. 2010 Mar 15; 23(3):608-19.
    View in: PubMed
    Score: 0.073
  30. Christians U, Klawitter J, Clavijo CF. Bioequivalence testing of immunosuppressants: concepts and misconceptions. Kidney Int Suppl. 2010 Mar; (115):S1-7.
    View in: PubMed
    Score: 0.073
  31. Clavijo C, Strom T, Moll V, Betts R, Zhang YL, Christians U, Bendrick-Peart J. Development and validation of a semi-automated assay for the highly sensitive quantification of Biolimus A9 in human whole blood using high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 01; 877(29):3506-14.
    View in: PubMed
    Score: 0.070
  32. Klawitter J, Bendrick-Peart J, Rudolph B, Beckey V, Klawitter J, Haschke M, Rivard C, Chan L, Leibfritz D, Christians U, Schmitz V. Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function. Chem Res Toxicol. 2009 Jan; 22(1):118-28.
    View in: PubMed
    Score: 0.067
  33. Ostojic M, Sagic D, Jung R, Zhang YL, Nedeljkovic M, Mangovski L, Stojkovic S, Debeljacki D, Colic M, Beleslin B, Milosavljevic B, Orlic D, Topic D, Karanovic N, Paunovic D, Christians U. The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study. Catheter Cardiovasc Interv. 2008 Dec 01; 72(7):901-8.
    View in: PubMed
    Score: 0.067
  34. Christians U, Schmitz V, Sch?ning W, Bendrick-Peart J, Klawitter J, Haschke M, Klawitter J. Toxicodynamic therapeutic drug monitoring of immunosuppressants: promises, reality, and challenges. Ther Drug Monit. 2008 Apr; 30(2):151-8.
    View in: PubMed
    Score: 0.064
  35. Serkova NJ, Christians U. Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood. Ther Drug Monit. 2005 Dec; 27(6):733-7.
    View in: PubMed
    Score: 0.054
  36. Cummins CL, Jacobsen W, Christians U, Benet LZ. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther. 2004 Jan; 308(1):143-55.
    View in: PubMed
    Score: 0.047
  37. Wiseman AC, Kam I, Christians U, Jani A, Bak T, Wachs M, Chan L. Fixed-dose sirolimus with reduced dose calcineurin inhibitor: the University of Colorado experience. Transplant Proc. 2003 May; 35(3 Suppl):122S-124S.
    View in: PubMed
    Score: 0.045
  38. Dambrin C, Klupp J, B?rsan T, Luna J, Suzuki T, Lam T, St?hr P, Hausen B, Christians U, Fitzgerald P, Berry G, Morris R. Sirolimus (rapamycin) monotherapy prevents graft vascular disease in nonhuman primate recipients of orthotopic aortic allografts. Circulation. 2003 May 13; 107(18):2369-74.
    View in: PubMed
    Score: 0.045
  39. Kirchner G, Mueller L, Winkler M, Loss M, Roechte F, Deters M, Christians U, Kaever V, Klempnauer J, Sewing K, Manns M. Long-term pharmacokinetics of the metabolites of everolimus and cyclosporine in renal transplant recipients. Transplant Proc. 2002 Sep; 34(6):2233-4.
    View in: PubMed
    Score: 0.043
  40. Serkova N, Jacobsen W, Niemann CU, Litt L, Benet LZ, Leibfritz D, Christians U. Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol. 2001 Jul; 133(6):875-85.
    View in: PubMed
    Score: 0.040
  41. Kuhn B, Jacobsen W, Christians U, Benet LZ, Kollman PA. Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. J Med Chem. 2001 Jun 07; 44(12):2027-34.
    View in: PubMed
    Score: 0.040
  42. Kirchner GI, Jacobsen W, Deters M, Christians U, Nashan B, Winkler M, Vidal C, Kaever V, Sewing K, Manns MP. Fast quantification method for sirolimus and its major metabolites. Transplant Proc. 2001 Feb-Mar; 33(1-2):1091-2.
    View in: PubMed
    Score: 0.039
  43. Ikonen TS, Gummert JF, Hayase M, Honda Y, Hausen B, Christians U, Berry GJ, Yock PG, Morris RE. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation. 2000 Sep 27; 70(6):969-75.
    View in: PubMed
    Score: 0.038
  44. Hausen B, Boeke K, Berry GJ, Christians U, Sch?ler W, Morris RE. Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ-RAD. Ann Thorac Surg. 2000 Mar; 69(3):904-9.
    View in: PubMed
    Score: 0.036
  45. Hausen B, Ikonen T, Briffa N, Berry GJ, Christians U, Robbins RC, Hook L, Serkova N, Benet LZ, Schuler W, Morris RE. Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation. 2000 Jan 15; 69(1):76-86.
    View in: PubMed
    Score: 0.036
  46. Ikonen TS, Gummert JF, Serkova N, Hayase M, Honda Y, Kobayase Y, Hausen B, Yock PG, Christians U, Morris RE. Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non-human primates: trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening. Transpl Int. 2000; 13 Suppl 1:S314-20.
    View in: PubMed
    Score: 0.036
  47. Hausen B, Boeke K, Berry GJ, Segarra I, Benet LZ, Christians U, Morris RE. Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. Transplantation. 1999 Apr 15; 67(7):956-62.
    View in: PubMed
    Score: 0.034
  48. Hausen B, Boeke K, Berry GJ, Segarra IT, Christians U, Morris RE. Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant. 1999 Feb; 18(2):150-9.
    View in: PubMed
    Score: 0.034
  49. Kirchner GI, Vidal C, Jacobsen W, Franzke A, Hallensleben K, Christians U, Sewing KF. Simultaneous on-line extraction and analysis of sirolimus (rapamycin) and ciclosporin in blood by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl. 1999 Jan 22; 721(2):285-94.
    View in: PubMed
    Score: 0.034
  50. Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF, Christians U. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther. 1998 Jun; 285(3):1104-12.
    View in: PubMed
    Score: 0.032
  51. Christians U, Sattler M, Schiebel HM, Kruse C, Radeke HH, Linck A, Sewing KF. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos. 1992 Mar-Apr; 20(2):186-91.
    View in: PubMed
    Score: 0.021
  52. Banerjee S, Gianino SM, Gao F, Christians U, Gutmann DH. Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes. Mol Cancer Ther. 2011 Feb; 10(2):279-91.
    View in: PubMed
    Score: 0.019
  53. Hausen B, Gummert J, Berry GJ, Christians U, Serkova N, Ikonen T, Hook L, Legay F, Schuler W, Schreier MH, Morris RE. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin. Transplantation. 2000 Feb 27; 69(4):488-96.
    View in: PubMed
    Score: 0.009
  54. Serkova N, Christians U, Fl?gel U, Pfeuffer J, Leibfritz D. Assessment of the mechanism of astrocyte swelling induced by the macrolide immunosuppressant sirolimus using multinuclear nuclear magnetic resonance spectroscopy. Chem Res Toxicol. 1997 Dec; 10(12):1359-63.
    View in: PubMed
    Score: 0.008
  55. Streit F, Christians U, Schiebel HM, Meyer A, Sewing KF. Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (rapamycin) by electrospray-MS/MS after incubation with human liver microsomes. Drug Metab Dispos. 1996 Nov; 24(11):1272-8.
    View in: PubMed
    Score: 0.007
  56. Streit F, Christians U, Schiebel HM, Napoli KL, Ernst L, Linck A, Kahan BD, Sewing KF. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem. 1996 Sep; 42(9):1417-25.
    View in: PubMed
    Score: 0.007
  57. Bader A, Knop E, B?ker KH, Crome O, Fr?hauf N, Gonschior AK, Christians U, Esselmann H, Pichlmayr R, Sewing KF. Tacrolimus (FK 506) biotransformation in primary rat hepatocytes depends on extracellular matrix geometry. Naunyn Schmiedebergs Arch Pharmacol. 1996 Mar; 353(4):461-73.
    View in: PubMed
    Score: 0.007
  58. Hoof T, Demmer A, Christians U, T?mmler B. Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycin. Eur J Pharmacol. 1993 Jun 15; 246(1):53-8.
    View in: PubMed
    Score: 0.006
  59. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992 Sep-Oct; 20(5):753-61.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)